Shares of drug developer Cogent Biosciences (COGT.O) rise 11.2% to $37.8 premarket Co says the U.S. Food and Drug Administration has accepted to review its experimental drug bezuclastinib for treating patients with a disease known as non-advanced systemic mastocytosis (NonAdvSM)
NonAdvSM is a rare condition where certain immune cells build up in the body more than they should, causing symptoms including skin flushing, stomach issues, tiredness and headaches
COGT says it has received a target action date of December 30 for bezuclastinib
Stock on track to break six-day losing streak if gains hold
As of last close, COGT was down 4.3% YTD

BUZZ-Cogent Biosciences rises after US FDA agrees to review rare‑disease drug